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Septic shock developed in 4 
(14.8%) of the 27 neutropenic patients 
with A. baumannii–associated bac-
teremia, and 2 (7.4%) of the 27 died 
(Table). However, we did not fi nd a 
statistically signifi cant association 
between death among patients with 
bacteremia caused by MDR A. bau-
manni (1 death) compared with death 
among those with bacteremia caused 
by A. baumannii strains susceptible to 
the carbapenems, ciprofl oxacin, and 
amikacin (1 death) (Table). This fi nd-
ing is similar to that described by Su-
nenshine et al. (1) in the general ICU 
population and in neutropenic cancer 
patients with bacteremia; however, 
multivariate analysis was not conduct-
ed to control for severity of illness and 
coexisting illness. In conclusion, neu-
tropenic cancer patients with bactere-
mia due to MDR A. baumannii infec-
tion do not appear to be at increased 
risk for death compared with patients 
with bacteremia due to antimicrobial 
drug–susceptible A. baumannii.
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Serogroup X in 
Meningococcal 
Disease, 
Western Kenya 
To the Editor: Although >12 
different serogroups of Neisseria 
meningitidis exist, most disease out-
breaks across the African meningitis 
epidemic belt are caused by serogroup 
A and, less frequently, by serogroups 
C and W135 (1). N. meningitidis se-
rogroup X was fi rst described in the 
1960s and has been found to cause a 
few cases of invasive disease across 
North America, Europe, and Africa 
(2). In Africa, small serogroup X out-
breaks have been described in Ghana 
(9 cases over a 2-year period) and in 
Niger (134 cases between 1995 and 
2000) (3,4). In 2006, however, 51% of 
1,139 confi rmed cases of meningococ-
cal meningitis in Niger were found to 
be caused by serogroup X (5). Before 
the 2005-06 meningococcal epidemic 
season, no published reports had de-
scribed serogroup X isolates in East 
Africa. We report the involvement 
of N. meningitidis serogroup X in an 
outbreak of meningococcal disease in 
Western Kenya.
In January 2006, the Ministry of 
Health of Kenya and Médecins sans 
Frontières were notifi ed of a suspect-
ed meningococcal disease outbreak in 
West Pokot District, bordering Ugan-
da, in Western Kenya. On the basis of 
the initial outbreak investigation, the 
outbreak was assessed to have begun 
in late December 2005. Subsequent 
active surveillance, using the same 
clinical case defi nition of sudden fever 
onset with stiff neck, altered mental 
status, or both, showed 74 suspected 
cases through mid-March 2006, with 
a case-fatality rate of 20%. No cases 
were reported after March 2006.
Over the course of the outbreak, 
cerebrospinal fl uid samples were ob-
tained from 18 patients. Due to low 
population density, poor access to 
seminomadic populations, and the 
Table. Risk factors and outcome for 27 neutropenic cancer patients with bacteremia 
due to multidrug-resistant (MDR) or drug-susceptible Acinetobacter baumannii infection
Characteristic
All patients, 
no. (%) 
(N = 27)
Patients with  
drug-susceptible
A. baumannii,  
no. (%)* 
(n = 12, 44%)
Patients with 
MDR
A. baumannii,
no. (%)* 
(n = 15, 56%)
Risk for bacteremia 
Central venous catheter 19 (70.4) 9 (75.0) 10 (66.7)
Acute leukemia 11 (40.7) 6 (50.0) 5 (33.3)
Previous prophylaxis with 
quinolones 14 (51.9) 8 (66.7) 6 (40.0)
Previous therapeutic treatment 
with cephalosporins 15 (55.6) 8 (66.7) 7 (46.7)
Previous therapeutic treatment 
with carbapenems 8 (29.6) 4 (33.3) 4 (26.7)
Outcome
Septic shock 4 (14.8) 2 (16.7) 2 (13.3)
Death 2 (7.4) 1 (8.3) 1 (6.7)
*Insignificant difference between patients with drug-susceptible infection and those with MDR 
infection (p<0.05 by univariate analysis). 
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Letters commenting on recent articles 
as well as letters reporting cases, out-
breaks, or original research are wel-
come. Letters commenting on articles 
should contain no more than 300 
words and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original article’s 
publication. Letters reporting cases, 
outbreaks, or original research should 
contain no more than 800 words and 
10 references. They may have one 
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.
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limited nature of the outbreak (rela-
tively small numbers dispersed over 
a wide geographic region), obtaining 
specimens from untreated patients in 
West Pokot proved diffi cult. Three of 
the 5 fi rst samples were found to show 
gram-negative diplococci on staining, 
the next 2 were negative on Pastorex 
rapid latex agglutination test (Bio-Rad 
Laboratories, Hercules, CA, USA) 
(during the outbreak investigation), 
and a subsequent 13 were sent to the 
African Medical and Research Foun-
dation (AMREF) laboratory in Nairo-
bi, Kenya, for culture and susceptibil-
ity testing. From these 13 specimens, 
2 yielded a pure growth of N. menin-
gitidis serogroup X, while no growth 
was observed for the remaining 11 
specimens. These 2 cultures were sub-
sequently confi rmed as serogroup X 
by the World Health Organization Col-
laborating Centre for Meningococci in 
Oslo, Norway. Multilocus sequence 
typing and sequencing of the porA 
and fetA genes as described (http://
pubmlst.org/neisseria/), showed that 
the infecting strain belonged to a new 
sequence type, ST-5403, and that it 
was subtype P1.19,26 and FetA type 
F3-27. This sequence type is unrelated 
to other serogroup X isolates from 
Africa, including those from the lat-
est serogroup X outbreak in Niger, but 
it resembles a sequence type isolated 
in the United States in the 1970s. In 
addition to the testing at AMREF and 
in the Oslo laboratory, the 13 samples 
were also analyzed by PCR at the US 
Naval Medical Research Unit No. 3 in 
Cairo, Egypt. Overall, 5 of these 13 
specimens were positive for serogroup 
X (including the 2 samples found to be 
serogroup X at AMREF and confi rmed 
by PCR in Oslo) and 1 each was posi-
tive for serogroups C, W135, and Y.
At the same time as this outbreak 
in Western Kenya, a meningococcal 
meningitis outbreak was being moni-
tored across the border in the Kar-
amoja region of northeastern Ugan-
da. Seminomadic populations move 
freely across the 2 countries, and we 
can assume that there was 1 menin-
gitis outbreak that started in eastern 
Uganda and spread to Western Kenya. 
Although initial laboratory testing in 
Uganda suggested the presence of se-
rogroup A, among 23 specimens sub-
sequently sent to the Oslo laboratory, 
11 were identifi ed as serogroup X by 
PCR and 3 were serogroup W135 (6). 
Therefore, the outbreaks in both Ke-
nya and Uganda involved multiple N. 
meningitidis serogroups. In West Po-
kot, Kenya, the Ministry of Health and 
Médecins sans Frontières conducted 
a vaccination campaign using the tri-
valent polysaccharide vaccine against 
serogroups A, C, and W135.
Before 2006, previous disease 
outbreaks caused by serogroup X had 
not reached the magnitude of those 
caused by serogroups A, C, or W135; 
they tended to evolve independently 
of the occurrence of both serogroups 
A and C and to be self-limited (3,4). 
Although most of Kenya is not includ-
ed in the African meningitis belt, large 
epidemics of meningococcal disease 
have been reported previously (7). In 
conclusion, we would like to highlight 
the presence of N. meningitidis sero-
group X in East Africa, its potential 
involvement in disease outbreaks, and 
the diffi culties it may cause for labora-
tory confi rmation and, consequently, 
for making an appropriate epidemic 
response.
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